Articles tagged with Prostate Tumors
Researchers at UCSF have discovered a new therapeutic target, SRC, present on up to half of all tumors, which can be targeted with antibody drugs. The enzyme, normally hidden inside cells, is exposed on the surface of tumor cells due to an overactive disposal system, making it an easy target for cancer-killing antibodies.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
Researchers at Weill Cornell Medicine will develop an AI system to identify patients with early signs of treatment-resistant prostate cancer. The project aims to improve clinical trials by predicting treatment outcomes and avoiding ineffective treatments for patients with specific tumor subtypes.
The European Association of Nuclear Medicine (EANM) has launched a new award to accelerate alpha radioligand therapy (α-RLT) research in prostate cancer. The EANM Young Scientist Network Award offers €40,000 in funding for promising researchers.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
Researchers at UH Seidman Cancer Center have developed a reliable tool to predict early biochemical response in metastatic hormone-sensitive prostate cancer patients. This framework enables clinicians to identify high-risk patients at diagnosis, guide early treatment discussions, and potentially improve patient outcomes.
Researchers at Case Western Reserve University have developed a new treatment for advanced prostate cancer that targets the PSMA protein. The treatment, called PSMA-1-DOTA, has been shown to effectively reduce salivary gland damage and eliminate severe side effects associated with current therapies.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Researchers have discovered a novel compound that degrades key proteins found in prostate cancer cells, blocking oncogenic androgen receptor signaling. The study found that levels of H2BNTac, p300 and CBP are elevated in prostate cancer compared to normal tissue.
A major international study has identified two enzymes that play a crucial role in helping prostate cancer cells grow and survive. Blocking these enzymes can destabilize the androgen receptor, making tumours more vulnerable to existing therapies.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
A new study found that Black men often view their primary-care providers as gatekeepers for prostate cancer screening, but are frequently dismissed from getting PSA tests. The study's lead author notes that PSA testing can catch the disease earlier and reduce mortality rates by up to 30% if done in the 40s rather than the 50s.
A new study found that a gene expression test can help guide therapy choices for prostate cancer patients with metastatic disease. The Decipher Prostate Genomic Classifier test identified groups of patients who are more likely to benefit from docetaxel chemotherapy, reducing the risk of death by 36%.
A new study found that one in six men with low-grade prostate cancer (GG1) actually have intermediate- or high-risk cancer when other clinical features are considered. This suggests that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment.
A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.
Researchers discovered two distinct ways mutation of the FOXA1 gene alters tumor formation and therapy resistance in prostate cancer in mouse models. The findings provide insight into how different classes of FOXA1 mutations operate, shedding light on the complex mechanisms driving prostate cancer progression.
Researchers found that stereotactic body radiotherapy (SBRT) is as safe as conventional treatment, with similar side effects and quality of life. SBRT shortens treatment time and may have biological advantages in targeting prostate cancer.
A new study by UCLA researchers shows that advanced MRI imaging and targeted focal therapy can help many men with low- to intermediate-risk prostate cancer safely stay on active surveillance long-term, avoiding follow-up biopsies and delaying or avoiding invasive treatments. The findings suggest that routine follow-up biopsy can now be...
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
Researchers have discovered genetic properties in prostate cancer that can be targeted to improve patient outcomes, particularly for Chinese men. The findings highlight the potential of precision medicine and more effective treatments.
Liquid biopsy analyzes circulating tumor components in body fluids to detect cancer at early stages, offering a safer and more dynamic alternative to traditional tissue biopsies. This non-invasive approach has shown promise in detecting various types of cancer, including lung, breast, colorectal, prostate, and gastric cancers.
Researchers mapped m6A patterns across 162 prostate cancer tumors and found that these modifications were closely tied to tumor aggressiveness. Analyzing m6A tags could help doctors predict disease behavior and determine personalized treatment strategies for patients with prostate cancer.
A new surgical technique called NeuroSAFE has been shown to preserve erectile function in men with prostate cancer, with 39% of patients experiencing no or mild dysfunction after treatment. This is compared to 23% of those who received standard surgery.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
Researchers developed an AI tool called Unfold AI to accurately estimate prostate tumor volume and identify patients likely to benefit from partial gland cryoablation. This approach shows promise in reducing treatment failures by over 70% and improving patient outcomes.
A study uncovered new genetic clues explaining why some prostate cancers grow slowly while others become life-threatening, identifying 223 mutations that determine tumor progression. The research shows germline and somatic variability work together to initiate and drive prostate cancer.
A new study by Rice University and Vanderbilt University researchers found that combining focused ultrasound with the existing protein therapy TRAIL can significantly reduce tumor size and burden in prostate cancer models. The therapy works by amplifying the anticancer effects of TRAIL via Piezo1 activation, which triggers cell death.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
A new study by UC San Francisco found a marked increase in advanced prostate cancer rates across California since doctors stopped routine screening, with death rates plateauing in most regions. The study emphasizes the need for screening that can identify fatal tumors without raising false alarms.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
Researchers found that immunosuppression in prostate cancer is associated with a specialised epithelial subtype. This interaction between the immune system and club-like epithelial cells can lead to treatment resistance in patients with advanced, treatment-resistant prostate cancer.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.
Researchers developed an AI model that can identify and measure aggressive prostate cancer lesions with high accuracy. The model's estimates of tumor size were associated with the likelihood of cancer recurrence or metastasis.
Researchers have found that tumors with a short-lived response to hormone therapy had a mutation in the p53 gene, which can be targeted by CDK2 inhibitors. A new study also provides updated dosing guidelines for stereotactic body radiation therapy (SBRT) to minimize complications in patients with spinal metastasis.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
Researchers developed a new mouse model to study prostate cancer spread, using CRISPR technology. The model revealed the routes of metastasis and patterns in cell seeding, providing valuable insights for better treatments.
A study published in Nature Communications found that the MYC gene is a common culprit driving prostate cancer progression. The research reveals how MYC activation attracts immune cells to the tumor but later helps hide it from immune detection, making it undetectable.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
A new study suggests that MRI scans can help doctors identify patients with more aggressive prostate cancer, allowing for earlier treatment or active surveillance. The research found that suspicious lesions on an MRI test were associated with a higher risk of advanced disease in five years.
A new deep learning model detects clinically significant prostate cancer on MRI with performance comparable to experienced abdominal radiologists. The model's prediction can be used as an adjunct to improve diagnostic performance and reduce false positives.
A new study reveals that Meteorin-like protein saps energy from T cells, severely limiting their ability to fight cancer. By understanding this signaling pathway, researchers may be able to develop targeted treatments to restore metabolic health and enhance the immune system's power against tumors.
Researchers from the University of Sheffield have developed a new form of immunotherapy using nanoparticles that delays the onset of resistance to hormone therapy in prostate cancer. This innovative approach stimulates immune cells called T cells to attack cancer cells, marking a significant breakthrough in treating prostate cancer.
Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.
A cross-sectional study found that men from disadvantaged neighborhoods had higher stress-related gene expression in their prostate tumors. This association suggests a potential link between neighborhood factors and aggressive prostate cancer.
Researchers developed a novel liquid biopsy technique to monitor disease evolution in metastatic prostate cancer patients. The method analyzes DNA and RNA in circulating extracellular vesicles, capturing tumor genomics and transcriptomic changes.
A phase 2 study found fluorine-18 PSMA-1007 PET/computed tomography to be superior to multiparametric MRI for locoregional staging of prostate cancer. The technology supports its use in the preoperative workflow for intermediate-risk and high-risk tumors.
Scientists have identified a new mechanism by which cells counteract a key cancer-promoting protein using an 'invisible' protein called RAI2. In cancer cell lines and patient samples, RAI2 levels are reduced in more severe and treatment-resistant forms of prostate cancer.
A new AI model has been shown to significantly improve the accuracy of diagnosing prostate cancer by 45 times compared to doctors' measurements alone. The system assists in mapping out the boundaries of cancerous tissue, reducing the risk of underestimation and enabling more precise treatment planning and effective surgical procedures.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
Researchers identified protein JUN as a potential therapeutic option to slow tumor growth in prostate cancer, contradicting previous findings that linked high JUN levels to increased tumor growth. The study showed that JUN slows tumor progression and improves immune response, providing a new starting point for therapy development.
A new alpha-ray therapeutic agent ([At-211] PSMA-5) has been developed to target prostate-specific membrane antigen (PSMA) in refractory prostate cancer patients. The therapy has shown efficacy in animal models and is now being tested in a first-in-human clinical trial.
A genomic study of over 5,000 veterans with advanced prostate cancer reveals significant differences in frequencies of alterations associated with race and ethnicity. Alterations in immunotherapy targets were more common in Black veterans, potentially leading to opportunities for precision-based therapy.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
A new study from Aarhus University has identified a gene that determines whether patients with prostate cancer develop metastases. The KMT2C gene is found to be crucial for the spread of prostate cancer and loss of this gene increases the risk of developing metastases.